The PD-1 expression balance between effector and regulatory T cells predicts the clinical efficacy of PD-1 blockade therapiesShogo Kumagai, Hiroyoshi Nishikawa, Vitaly Kochin et al.|Nature Immunology|2020Cited by 810
Randomized Phase 2 Study of Osimertinib Plus Bevacizumab Versus Osimertinib for Untreated Patients With Nonsquamous NSCLC Harboring EGFR Mutations: WJOG9717L StudyHirotsugu Kenmotsu, Toshiaki Takahashi, Kazushige Wakuda et al.|Journal of Thoracic Oncology|2022Cited by 158
Identification of Biological Properties of Intralymphatic Tumor Related to the Development of Lymph Node Metastasis in Lung AdenocarcinomaKeisuke Kirita, Atsushi Ochiai|PLoS ONE|2013Cited by 13